Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.

Autor: Raga MG; Medical Oncology Department, CIBERONC, Hospital General Universitario de Valencia, Valencia, Spain. mir_gil@hotmail.com., Pérez IP; Medical Oncology Department, Hospital Provincial de Castellón, Castellón, Spain., Veiga RC; Medical Oncology Department, Hospital Universitario Doctor Peset de Valencia, Valencia, Spain., Sosa MM; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Aguilera MJS; Medical Oncology Department, CIBERONC, Hospital General Universitario de Valencia, Universitat de València, Valencia, Spain., Rodríguez PL; Medical Oncology Department, Hospital Arnau de Vilanova, Valencia, Spain., Bonastre MTT; Medical Oncology Department, Hospital Universitario de La Ribera, Alzira, Spain., Urtasun JA; Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Abad LP; Medical Oncology Department, Hospital de Sagunto, Sagunto, Spain., Hernández IB; Medical Oncology Department, Hospital Provincial de Castellón, Castellón, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 May; Vol. 25 (5), pp. 1455-1462. Date of Electronic Publication: 2023 Feb 01.